Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics (PLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Protalix Biotherapeutics 2 SNUNIT ST SCIENCE PARK POB 455 CARMIEL L3 20100 ISR

P: 972-4988-9488 F: 972-498-8948

Description:

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Key Statistics

Overview:

Market Capitalization, $K 32,644
Shares Outstanding, K 148,382
Annual Sales, $ 34,240 K
Annual Net Income, $ -26,460 K
Last Quarter Sales, $ 12,250 K
Last Quarter Net Income, $ -7,740 K
60-Month Beta 2.73
% of Insider Shareholders 3.30%
% of Institutional Shareholders 8.39%
Float, K 143,485
% Float 96.70%

Growth:

1-Year Return -52.76%
3-Year Return -54.17%
5-Year Return -89.47%
5-Year Revenue Growth 197.48%
5-Year Earnings Growth 40.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/07/19
Earnings Per Share ttm -0.13
EPS Growth vs. Prev Qtr 60.00%
EPS Growth vs. Prev Year 80.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-10 on 01/03/07

PLX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -3.49
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) 0.00
Return-on-Assets (Before Tax) -14.86
Profit Margin % -77.28
Net Margin % -267.37
Debt/Equity N/A
Price/Sales 1.00
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.45
Interest Coverage N/A
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar